FDA Halts Emergency Approval of COVID-19 Blood Plasma Treatment
The Food and Drug Administration’s emergency authorization for blood plasma as a treatment for the coronavirus has been put on hold to allow for more data to be reviewed, according to a report.
An emergency approval could still be issued by the FDA in the near future, H. Clifford Lane, clinical director at the National Institute of Allergy and Infectious Diseases, told the New York Times.
Several top health experts — including Dr. Anthony Fauci and Dr. Francis Collins, director of the National Institutes of Health — intervened last week, saying that data on the treatment was too weak, two senior administration officials told the newspaper.
Read More at the New York Post
